Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

On behalf of International Society of Liquid Biopsy (

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Introduction: In the current era of personalized medicine, liquid biopsy has acquired a relevant importance in patient management of advanced stage non-small cell lung cancer (NSCLC). As a matter of fact, liquid biopsy may supplant the problem of inadequate tissue for molecular testing. The term ‘liquid biopsy’ refers to a number of different biological fluids, but is most clearly associated with plasma-related platforms. It must be taken into account that pre-analytical processing and the selection of the appropriate technology according to the clinical context may condition the results obtained. In addition, novel clinical applications beyond the evaluation of the molecular status of predictive biomarkers are currently under investigation. Areas covered: This review summarizes the available evidence on pre-analytical issues and different clinical applications of liquid biopsies in NSCLC patients. Expert opinion: Liquid biopsy should be considered not only as a valid alternative but as complementary to tissue-based molecular approaches. Careful attention should be paid to the optimization and standardization of all phases of liquid biopsy samples management in order to determine a significant improvement in either sensitivity or specificity, while significant reducing the number of ‘false negative’ or ‘false positive’ molecular results.

Original languageEnglish (US)
JournalExpert Review of Molecular Diagnostics
StateAccepted/In press - 2021


  • biomarkers
  • CTC
  • ctDNA
  • Liquid biopsy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this